Heartflow, Inc. (HTFL): what the price assumes

In the published model solve dated 2026-Q2, anchored at $27.19, Heartflow, Inc. (HTFL) is priced for today's economics sustained for ~16.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/HTFL

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.

Solve inputs: computed at a 12.8% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.5 years.

Reconcile: at the x-ray's 9.3% required return this reads ~8.3 years; the models below use their own rates.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=6)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.

Bullet Takeaways

• Heartflow sells an AI-driven analysis of coronary CT scans that helps cardiologists assess heart-disease risk without an invasive procedure, a software-like business that grew revenue about 40% in 2025 to $176 million and guides to roughly 29% to 32% growth in 2026.
• The defining risk is reimbursement: the business depends on insurers paying for its analyses, and the company lists "changes in reimbursement by current or potential payors" among the factors that could move its results.
• Watch the path to profitability against a 2025 net loss of roughly $117 million and a targeted midterm gross margin of about 85%; the company holds enough cash to fund the journey but is still burning.

Bull Case

Heartflow is a growth-stage medical-technology company, and its numbers should be read that way: negative earnings are the investment, and the question is whether revenue is accelerating fast enough, at high enough gross margins, to reach profitability before the cash runs low. On that test the early evidence is strong. Revenue grew about 40% in 2025 to $176 million and accelerated to 41% year-over-year growth in the first quarter of 2026, reaching $52.6 million, prompting the company to raise full-year 2026 guidance to $228 million to $232 million. A company speeding up rather than decelerating after its IPO is doing the one thing a growth investor most wants to see.

The economics underneath that growth look like software, not hardware. Heartflow analyzes a CT scan and returns a result; once the algorithm exists, each additional analysis costs little to deliver. Management is targeting a midterm non-GAAP gross margin of about 85% through operational gains, the kind of structural margin that lets revenue growth eventually overwhelm a fixed cost base and turn losses into profits. That margin profile is why the price can be set against sales today: the market is valuing the future operating profit those gross margins imply.

The reimbursement tailwind is the most important recent development for durability. UnitedHealthcare and Cigna began covering Heartflow's Plaque Analysis on October 1, 2025, adding two of the largest commercial payers to the coverage base. Broader payer coverage is what converts clinical adoption into recurring, billable volume, and rapid expansion of the installed base of CT systems running the analysis is what drove total revenue up 41%. The bull case is a high-gross-margin, fast-growing diagnostic platform whose addressable market widens each time another payer signs on.

Bear Case

The external variable with the most leverage over Heartflow, and the one the price is most exposed to, is reimbursement. The entire revenue model assumes payers keep paying for the analysis, and the company says as much, listing "changes in reimbursement by current or potential payors" among the forces that could move its business. UnitedHealthcare and Cigna coverage beginning in October 2025 was a positive, but coverage decisions can be narrowed, repriced, or reversed, and a single large payer pulling back or cutting the rate would hit revenue directly. A company priced at roughly 13 times sales has built years of uninterrupted reimbursement and adoption into the number; the payer landscape is not under its control.

The profitability gap is wide and the burn is real. The company lost about $117 million in 2025, more than the year before, and the operating margin runs deeply negative. It holds roughly $187 million of net cash, which funds the journey for now, but the bear case is that reaching breakeven requires the revenue ramp to continue uninterrupted for years while the company keeps spending to expand its installed base and payer coverage. If growth slows before the gross-margin leverage kicks in, the company faces the classic growth-stage squeeze: raise capital from a weaker position, or pull back on the spending that drives the growth in the first place.

The valuation assumes an outcome that is far from guaranteed. With no normal operating profit yet, the price is set against revenue, and it implies the business eventually earns an operating margin around 30% while growing at its self-funding ceiling for some sixteen years. Read that as a direction, not a measurement, but the direction is demanding: it is the profile of a category-defining platform, not a contested diagnostic. The asset-value and growth-DCF lenses both read the price as expensive; only the revenue-multiple and earnings-power-on-future-margins lenses support it. The bear case is that any combination of slower adoption, a reimbursement setback, or competitive entry from larger imaging or cardiology players compresses that long, smooth ramp the price requires.

Valuation

Heartflow does not yet earn a normal operating profit, so the price is set against its sales rather than its earnings. At about 13 times revenue, the price implies the business eventually reaches an operating margin near 30% and grows revenue at its self-funding ceiling for roughly sixteen years. Read those figures as a direction rather than a solved point, but the shape of the bet is clear: this is a long-duration growth story where today's losses are an investment and the value lives entirely in the operating profit the high gross margins are supposed to produce later.

The methods split exactly as they do for a fast-growing loss-maker. The asset-value lenses read the price as far above the company's book value, which is normal for a software-like business with little hard capital. The growth-DCF reads it as expensive because the model has to discount profits that are still years out. What supports the price are the revenue-multiple comparison to peers and the methods that credit the future margin: the relative-valuation and earnings-power-on-eventual-margin lenses land near the price. The disagreement is really a disagreement about timing, between methods that price what exists today and methods that price what the gross-margin trajectory implies.

Solvency is the part of the picture that bounds the downside, with a caveat. The company holds roughly $187 million of net cash against modest debt, which funds the operating losses for now. But it is still burning cash, and because it has no demonstrated through-cycle operating margin, a clean years-to-repay or coverage figure cannot be computed honestly; the relevant metric is runway, and the runway depends on how fast the losses narrow. The valuation does not rest on the balance sheet so much as on duration: whether the revenue ramp and the 85% midterm gross-margin target arrive fast enough to turn the cash position from a countdown into a cushion. That, not any single multiple, is the wager.

Catalysts

The clearest catalyst is the revenue trajectory measured against the raised 2026 guidance of $228 million to $232 million, roughly 29% to 32% growth, after first-quarter revenue rose 41% to $52.6 million. Each quarter is a test of whether the post-IPO acceleration holds, and a guidance raise versus a trim is the most direct signal for a stock priced on its sales. The CEO has described the company as entering 2026 with the strongest momentum in its history, a bar the prints now have to clear.

Reimbursement and the margin path are the other two threads. UnitedHealthcare and Cigna coverage of Plaque Analysis began on October 1, 2025, so the read to watch is whether additional payers follow and whether existing coverage broadens, since payer breadth is what converts adoption into billable volume. On the cost side, progress toward the targeted midterm gross margin near 85% and a narrowing operating loss are the markers that the model is bending toward profitability. The next earnings call's commentary on payer wins and the loss trajectory will show whether the long ramp the valuation requires is on schedule.

Peer Cohorts (Per Segment, With Filing Citations)

Heartflow (consolidated) (reported)

• IRTC (iRhythm Holdings, Inc.)
• FY2025 10-K: . 88 IRHYTHM TECHNOLOGIES, INC. Notes to Consolidated Financial Statements 1. ORGANIZATION AND DESCRIPTION OF BUSINESS iRhythm Technologies, Inc. ("the Company") was incorporated in the state of Delaware in September 2006. On January 12, 2026, the Company implemented a corporate holding company structure that resulted…
• FY2025 10-K: …clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Since first receiving clearance from the U.S. Food and Drug Administration ("FDA") for the Company's technology in 2009, the Company has supported physician and patient use of its…
• NVCR (NovoCure Limited)
• FY2025 10-K: …per share data) Note 1: Organization NovoCure Limited (including its consolidated subsidiaries, the "Company") was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of Tumor Treating Fields ("TTFields") devices, including Optune Gio, Optune Lua…
• FY2025 10-K: …developments and their impact on us. Forward-looking statements contained in this report constitute our expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commission and are not statements of historical fact. You can identify these statements by the fact…
• GKOS (GLAUKOS Corp)
• FY2025 10-K: 1, 2025, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows…
• FY2025 10-K: …at December 31, 2025 or December 31, 2024. Realized gains and losses and declines in value, if any, judged to be other‑than‑temporary on available for sale securities, are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss previously reported as a separate…
• INSP (Inspire Medical Systems, Inc.)
• FY2025 10-K: …consolidated balance sheets. We had $ 0.1 million of unrecognized loss and $ 0.2 of unrecognized gain in our accumulated other comprehensive income balance as of December 31, 2025 and 2024, respectively. Investments Our investments are classified as available-for-sale and consisted of the following: December 31, 2025…
• FY2025 10-K: "), European Union ("EU"), Medical Devices Regulation, and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. Inspire therapy received premarket approval from the FDA in 2014 and has…
• PRCT (PROCEPT BioRobotics Corporation)
• FY2025 10-K: …solutions that positively impact patients and drive value. The key elements of our growth strategy are: • Grow our install base of robotic systems by driving adoption of Aquablation therapy among urologists. In the United States, we are focused on driving adoption of Aquablation therapy among urologists that perform…
• FY2025 10-K: …future commercial, regulatory and reimbursement efforts to drive growth. • Invest in research and development to drive continuous improvements and innovation. We are currently developing additional and next generation technologies to support and improve Aquablation therapy to further satisfy the evolving needs of…
• TNDM (Tandem Diabetes Care, Inc.)
• FY2025 10-K: …sells, and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company offers an insulin pump portfolio, which includes both the t:slim X2 and the Tandem Mobi. Both pumps feature Control-IQ+ technology,…
• FY2025 10-K: …us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0001438133 tndm:DistributorDMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31 0001438133 tndm:DistributorDMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31…
• ATRC (AtriCure, Inc.)
• FY2025 10-K: …designed primarily for the surgical ablation of cardiac tissue, the exclusion of the left atrial appendage, and to block pain by temporarily ablating peripheral nerves. These devices are developed and marketed to a broad base of medical centers globally. Management considers all such sales to be part of the single…
• FY2025 10-K: …us-gaap:SalesRevenueNetMember 2024-01-01 2024-12-31 0001323885 atrc:MedicalDevicesMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2023-01-01 2023-12-31 0001323885 atrc:MedicalDevicesMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2025-01-01 2025-12-31…
• BFLY (Butterfly Network, Inc.)
• FY2025 10-K: …offering conventional ultrasound systems. While Butterfly's target is often non-traditional ultrasound users, we do compete with both traditional ultrasound manufacturers and other handheld ultrasound systems. However, Butterfly's semiconductor technology differentiates us from our competitors in many ways, including…
• FY2025 10-K: 31, 2025, a substantial majority of our revenues were derived from sales to customers based in the United States. We believe our differentiated Butterfly handheld device and our growing user base of Butterfly practitioners, with sales to or agreements with most of the 100 largest U.S. healthcare systems and devices…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.